You are here

News

subscribe

The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.

23 July 2020

Injectable PrEP – an exciting tool, but no silver bullet for adherence

We talk to Giffin Daughtridge, CEO of medical diagnostics company, UrSure, about treatment adherence and the impact of long-acting cabotegravir as injectable PrEP.

21 May 2020

Global trial of long-acting injectable PrEP for gay men and trans women stopped early following success

Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.